Development of a PIV-vectored RSV vaccine: Preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults

This publication has 29 references indexed in Scilit:

• The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
  Vaccine, 2007
• A Bovine Parainfluenza Virus Type 3 Vaccine Is Safe and Immunogenic in Early Infancy
  The Journal of Infectious Diseases, 2005
• Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants
  The Journal of Infectious Diseases, 2005
• Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys
  Journal of Virology, 2004
• Bronchiolitis‐Associated Mortality and Estimates of Respiratory Syncytial Virus–Associated Deaths among US Children, 1979–1997
  The Journal of Infectious Diseases, 2001
• Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy
  The Journal of Infectious Diseases, 2000
• Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants
  The Pediatric Infectious Disease Journal, 1996
• A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children
  The Journal of Infectious Diseases, 1995
• Parainfluenza Virus Type 3: Seasonality and Risk of Infection and Reinfection in Young Children
  The Journal of Infectious Diseases, 1984
• Parenteral Administration of Live Respiratory Syncytial Virus Vaccine: Results of a Field Trial
  The Journal of Infectious Diseases, 1982